Effentora

Țară: Uniunea Europeană

Limbă: engleză

Sursă: EMA (European Medicines Agency)

Cumpara asta acum

Prospect Prospect (PIL)
04-04-2024

Ingredient activ:

fentanyl

Disponibil de la:

Teva B.V.

Codul ATC:

N02AB03

INN (nume internaţional):

fentanyl

Grupul Terapeutică:

Analgesics

Zonă Terapeutică:

Pain; Cancer

Indicații terapeutice:

Effentora is indicated for the treatment of breakthrough pain (BTP) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain. BTP is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain. Patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer. ,

Rezumat produs:

Revision: 28

Statutul autorizaţiei:

Authorised

Data de autorizare:

2008-04-04

Prospect

                                44
B. PACKAGE LEAFLET
45
PACKAGE LEAFLET: INFORMATION FOR THE USER
EFFENTORA 100 MICROGRAMS BUCCAL TABLETS
EFFENTORA 200 MICROGRAMS BUCCAL TABLETS
EFFENTORA 400 MICROGRAMS BUCCAL TABLETS
EFFENTORA 600 MICROGRAMS BUCCAL TABLETS
EFFENTORA 800 MICROGRAMS BUCCAL TABLETS
Fentanyl
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Effentora is and what it is used for
2.
What you need to knowbefore you use Effentora
3.
How to use Effentora
4.
Possible side effects
5.
How to store Effentora
6.
Contents of the pack and other information
1.
WHAT EFFENTORA IS AND WHAT IT IS USED FOR
The active substance of Effentora is fentanyl citrate. Effentora is a
pain-relieving medicine known as
an opioid, which is used to treat breakthrough pain in adult patients
with cancer who are already taking
other opioid pain medicines for their persistent (around-the-clock)
cancer pain.
Breakthrough pain is additional, sudden pain that occurs in spite of
you having taken your usual opioid
pain-relieving medicines.
2.
WHAT YOU NEED TO KNOW BEFORE YOU USE EFFENTORA
DO NOT USE EFFENTORA:
•
If you are not regularly using a prescribed opioid medicine (e.g
codeine, fentanyl, hydromorphone,
morphine, oxycodone, pethidine), every day on a regular schedule, for
at least a week, to control
your persistent pain. If you have not been using these medicines you MUST NOT
use Effentora,
because it may increase the risk that breathing could become
dangerously slow and/or shallow, or
even stop.
•
If you are allergic to fentanyl or any of the ot
                                
                                Citiți documentul complet
                                
                            

Caracteristicilor produsului

                                1
_ _
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Effentora 100 micrograms buccal tablets
Effentora 200 micrograms buccal tablets
Effentora 400 micrograms buccal tablets
Effentora 600 micrograms buccal tablets
Effentora 800 micrograms buccal tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Effentora 100 micrograms buccal tablets
Each buccal tablet contains 100 micrograms fentanyl (as citrate).
Excipient with known effect: Each tablet contains 10 mg of sodium.
Effentora 200 micrograms buccal tablets
Each buccal tablet contains 200 micrograms fentanyl (as citrate).
Excipient with known effect: Each tablet contains 20 mg of sodium.
Effentora 400 micrograms buccal tablets
Each buccal tablet contains 400 micrograms fentanyl (as citrate).
Excipient with known effect: Each tablet contains 20 mg of sodium.
Effentora 600 micrograms buccal tablets
Each buccal tablet contains 600 micrograms fentanyl (as citrate).
Excipient with known effect: Each tablet contains 20 mg of sodium.
Effentora 800 micrograms buccal tablets
Each buccal tablet contains 800 micrograms fentanyl (as citrate).
Excipient with known effect: Each tablet contains 20 mg of sodium.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Buccal tablet.
Effentora 100 micrograms buccal tablets
Flat-faced, white, round bevelled-edge tablet, embossed on one side
with a “C” and on the other side
with “1”.
Effentora 200 micrograms buccal tablets
Flat-faced, white, round bevelled-edge tablet, embossed on one side
with a “C” and on the other side
with “2”.
Effentora 400 micrograms buccal tablets
Flat-faced, white, round bevelled-edge tablet, embossed on one side
with a “C” and on the other side
with “4”.
Effentora 600 micrograms buccal tablets
Flat-faced, white, round bevelled-edge tablet, embossed on one side
with a “C” and on the other side
with “6”.
3
Effentora 800 micrograms buccal tablets
Flat-faced, white, round bevelled-edge tablet, embossed on one side
with a “C” and on
                                
                                Citiți documentul complet
                                
                            

Documente în alte limbi

Prospect Prospect bulgară 04-04-2024
Caracteristicilor produsului Caracteristicilor produsului bulgară 04-04-2024
Raport public de evaluare Raport public de evaluare bulgară 14-04-2014
Prospect Prospect spaniolă 04-04-2024
Caracteristicilor produsului Caracteristicilor produsului spaniolă 04-04-2024
Raport public de evaluare Raport public de evaluare spaniolă 14-04-2014
Prospect Prospect cehă 04-04-2024
Caracteristicilor produsului Caracteristicilor produsului cehă 04-04-2024
Raport public de evaluare Raport public de evaluare cehă 14-04-2014
Prospect Prospect daneză 04-04-2024
Caracteristicilor produsului Caracteristicilor produsului daneză 04-04-2024
Raport public de evaluare Raport public de evaluare daneză 14-04-2014
Prospect Prospect germană 04-04-2024
Caracteristicilor produsului Caracteristicilor produsului germană 04-04-2024
Raport public de evaluare Raport public de evaluare germană 14-04-2014
Prospect Prospect estoniană 04-04-2024
Caracteristicilor produsului Caracteristicilor produsului estoniană 04-04-2024
Raport public de evaluare Raport public de evaluare estoniană 14-04-2014
Prospect Prospect greacă 04-04-2024
Caracteristicilor produsului Caracteristicilor produsului greacă 04-04-2024
Raport public de evaluare Raport public de evaluare greacă 14-04-2014
Prospect Prospect franceză 04-04-2024
Caracteristicilor produsului Caracteristicilor produsului franceză 04-04-2024
Raport public de evaluare Raport public de evaluare franceză 14-04-2014
Prospect Prospect italiană 04-04-2024
Caracteristicilor produsului Caracteristicilor produsului italiană 04-04-2024
Raport public de evaluare Raport public de evaluare italiană 14-04-2014
Prospect Prospect letonă 04-04-2024
Caracteristicilor produsului Caracteristicilor produsului letonă 04-04-2024
Raport public de evaluare Raport public de evaluare letonă 14-04-2014
Prospect Prospect lituaniană 04-04-2024
Caracteristicilor produsului Caracteristicilor produsului lituaniană 04-04-2024
Raport public de evaluare Raport public de evaluare lituaniană 14-04-2014
Prospect Prospect maghiară 04-04-2024
Caracteristicilor produsului Caracteristicilor produsului maghiară 04-04-2024
Raport public de evaluare Raport public de evaluare maghiară 14-04-2014
Prospect Prospect malteză 04-04-2024
Caracteristicilor produsului Caracteristicilor produsului malteză 04-04-2024
Raport public de evaluare Raport public de evaluare malteză 14-04-2014
Prospect Prospect olandeză 04-04-2024
Caracteristicilor produsului Caracteristicilor produsului olandeză 04-04-2024
Raport public de evaluare Raport public de evaluare olandeză 14-04-2014
Prospect Prospect poloneză 04-04-2024
Caracteristicilor produsului Caracteristicilor produsului poloneză 04-04-2024
Raport public de evaluare Raport public de evaluare poloneză 14-04-2014
Prospect Prospect portugheză 04-04-2024
Caracteristicilor produsului Caracteristicilor produsului portugheză 04-04-2024
Raport public de evaluare Raport public de evaluare portugheză 14-04-2014
Prospect Prospect română 04-04-2024
Caracteristicilor produsului Caracteristicilor produsului română 04-04-2024
Raport public de evaluare Raport public de evaluare română 14-04-2014
Prospect Prospect slovacă 04-04-2024
Caracteristicilor produsului Caracteristicilor produsului slovacă 04-04-2024
Raport public de evaluare Raport public de evaluare slovacă 14-04-2014
Prospect Prospect slovenă 04-04-2024
Caracteristicilor produsului Caracteristicilor produsului slovenă 04-04-2024
Raport public de evaluare Raport public de evaluare slovenă 14-04-2014
Prospect Prospect finlandeză 04-04-2024
Caracteristicilor produsului Caracteristicilor produsului finlandeză 04-04-2024
Raport public de evaluare Raport public de evaluare finlandeză 14-04-2014
Prospect Prospect suedeză 04-04-2024
Caracteristicilor produsului Caracteristicilor produsului suedeză 04-04-2024
Raport public de evaluare Raport public de evaluare suedeză 14-04-2014
Prospect Prospect norvegiană 04-04-2024
Caracteristicilor produsului Caracteristicilor produsului norvegiană 04-04-2024
Prospect Prospect islandeză 04-04-2024
Caracteristicilor produsului Caracteristicilor produsului islandeză 04-04-2024
Prospect Prospect croată 04-04-2024
Caracteristicilor produsului Caracteristicilor produsului croată 04-04-2024
Raport public de evaluare Raport public de evaluare croată 14-04-2014

Căutați alerte legate de acest produs

Vizualizați istoricul documentelor